Similarly, treatment with temozolomide (TMZ) induces the overexpression of activating transcription factor 4 (ATF4), which promotes DNA damage-inducible transcript 4 (DDIT4)/GLUT3 signaling and enhances resistance to TMZ in GBM (Ho et al. 2020). The gene discussed is ATF4; the disease is glioblastoma.